- £208.73bn
- £226.50bn
- $54.07bn
- 78
- 16
- 97
- 73
REG - AstraZeneca PLC - 9M and Q3 2025 results
AnnouncementREG - AstraZeneca PLC - Result of General Meeting
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Director Declaration
AnnouncementREG - AstraZeneca PLC - Koselugo (selumetinib) approved in the EU
AnnouncementREG - AstraZeneca PLC - Tezspire Approved in EU for CRSwNP
AnnouncementREG - AstraZeneca PLC - US FDA Approves Tezspire in CRSwNP
AnnouncementREG - AstraZeneca PLC - Positive CHMP opinion for subcutaneous Saphnelo
AnnouncementREG - AstraZeneca PLC - Agreement with US Govt to lower medicine prices
AnnouncementRCS - LHH - LHH, EZRA's AI Leadership Transformation Program
AnnouncementREG - AstraZeneca PLC - Baxdrostat met primary endpoint in Bax24 Ph3 trial
AnnouncementREG - AstraZeneca PLC - Datroway improved OS and PFS in TROPION-Breast02
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Enhertu improved IDFS in early BC in DB-05
AnnouncementREG - AstraZeneca PLC - AZN harmonises listing structure
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementRCS - Redx Pharma Limited - Redx Pharma to present new Phase 2a data at ERS
AnnouncementREG - AstraZeneca PLC - Koselugo recommended for EU approval
AnnouncementREG - AstraZeneca PLC - Tezspire Recommended for Approval in EU for CRSwNP
Announcement